Immunologically modified MnFe2O4 nanoparticles to synergize photothermal therapy and immunotherapy for cancer treatment

Benqing Zhou,Qiang Wu,Meng Wang,Ashley Hoover,Xin Wang,Feifan Zhou,Nataliya Smith,Debra Saunders,Jun Song,Junle Qu,Rheal A. Towner,Wei R. Chen

DOI: https://doi.org/10.1016/j.cej.2020.125239

IF: 15.1

2020-09-01

Chemical Engineering Journal

Abstract:Immunotherapy has been a promising candidate for cancer treatment. The combination of photothermal therapy (PTT) and immunotherapy have shown to cause tumor ablation and induce host immune response. However, this strategy is often hampered by a limited immune response and undesirable immunosuppression. In this work, we developed an immunologically modified nanoplatform, using ovalbumin (OVA)-coated PEGylated MnFe₂O₄ nanoparticles (NPs) loaded with R837 immunoadjuvant (R837-OVA-PEG-MnFe₂O₄ NPs) to synergize PTT and immunotherapy for the treatment of breast cancer. The designed R837-OVA-PEG-MnFe₂O₄ NPs are able to elicit significant immune responses <i>in vitro</i> and <i>in vivo</i>. MnFe₂O₄ NPs also allowed for a reduction of systemic immunosuppression through downregulation of M2-associated cytokines. More importantly, the R837-OVA-PEG-MnFe₂O₄ NPs under laser irradiation effectively inhibited tumor growth and prevented lung metastases, leading to a prolonged survival time and improved survival rate. In addition, the designed multitasking MnFe₂O₄ NPs showed as a good contrast agent for magnetic resonance (MR) imaging to detect orthotopic breast tumor <i>in vivo</i>. Our work provides a novel strategy for combined PTT and improved immunotherapy in the treatment of breast and other metastatic cancers.

engineering, chemical, environmental